Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-04-03
2009-08-11
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S218100, C424S093200, C435S235100, C435S320100
Reexamination Certificate
active
07572453
ABSTRACT:
Chimeric alphaviruses andalphavirusreplicon particles are provided including methods of making and using same. Specifically,alphavirusparticles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimericalphavirusparticle, are disclosed.
REFERENCES:
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 6015686 (2000-01-01), Dubensky, Jr. et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6184024 (2001-02-01), Lai et al.
patent: WO 95/07994 (1995-03-01), None
patent: WO 97/38087 (1997-10-01), None
patent: WO 98/37911 (1998-09-01), None
patent: WO 98/53077 (1998-11-01), None
patent: WO 99/18226 (1999-04-01), None
Berglund et. al., “Enhancing immune responses using suicidal DNA vaccines,”Nat. Biotech 16:562-565 (1998).
Berglund et. al., “Immunization with recombinant semliki forest virus induces protection against influenza challenge in mice,”Vaccine 17:497-507 (1999).
Davis et. al., “In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA clone: Analysis of a Viable Deletion Mutant,”Virology, 171: 189-204 (1989).
Davis et. al., “Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles,”J. Vior. 17:371-378 (2000).
Dubensky et al., “Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer.”J. Vior. 70:508-519 (1996).
Fields et. al., “Alphaviruses,”Virology, (Third Edition) pp. 843-848 (1996).
Frolov, Elena et. al., “Packaging signals in alpha virus,”J. Virology71(1):248-258 (1997).
Frolov, Ilya et. al, “Sindbis virus replicons and Sindbis Virus: Assembly of Chimeras and of particles Deficient in virus RNA,”J. Virology71(4):2819-2829, (1997).
Gardner et. al. “Infection of Human Dendritic Cells by a Sinbis Virus Replicon Vector is Determined by a Single Amino Acid Substituion in the E2 Glycoprotein,:”J. Virology, vol. 74, No. 24 (2000), pp. 11849-11857.
Guirakhoo et. al., “Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine,”J. Virology75(16):7290-7304(2001).
Hariharan et. al., “DNA immunization against Herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector,”J. Vior. 72:950-958 (1998).
Kim, Kyongmin Hwang, et. al., “Adaptive mutations in Sindbis Virus E2 and Ross River virus E1 that allow efficient budding of chimeric viruses,”J. Virology74(6): 2663-2670 (2000).
Kuhn, et. al., “Chimeric Sindbis-Ross River viruses to study interactions between alphavirus nonstructural and structural regions,”J. Virology70(11):7900-7909 (1996).
Lee et. al., “Identification of a protein binding site on the surface of the alphavirus nucleocapsid and its implication in virus assembly,”Structure, 4: 531-431 (1996).
Liljestrom, “A new generation of animal cell expression vectors based on the Semliki Forest virus replicon,”Bio/Technology 9:1356-1361 (1991).
Lopez, Susana et. al., “Nucleocapsid-glycoprotein interactions required for assembly of alphavirus,”J. Virology, 68(3): 1316-1323, 1994.
Monath et. al., “Chimeric yellow fever virus 17D—Japanese Encephalitis virus vaccine: dose-response effectiveness and extended safety testing in Rhesus monkeys.”J. Virology74(4):1742-1751 (2000).
Owen et. al., Identification of a Region in the Sindbis Virus Nucleocapsid Protein that is Involved in the Specificity of RNA Encapsidation,J. Virology, 70(5):2757-2763 (1996).
Polo et. al., “Stable alphavirus packaging cell lines for Sindbis virus-and Semliki Forest virus-derived vectors,”PNAS 96:4598-4603 (1999).
Powers et. al., “The use of chimeric Venezuelan Equine Encephalitis viruses as an approach for the molecular identification of natural virulence determinants,”J. Virology74(9):4258-4263 (2000).
Pushko et. al., “Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.”Virology 239:389-401 (1997).
Schlesinger and Dubensky, “Alphavirus vectors for gene expression and vaccines,”Curr. Opin. Biotechnol. 10:434-439 (1999).
Schoepp et. al., “Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates,”Virology302:299-309 (2002).
Smerdou, Cristian, et. al., “Alphavirus vectors: from protein production to gene therapy,”Gene Therapy and Regulation, 1(1):33-63 (2000).
Smyth et. al., “Efficient multiplication of a Semliki Forest virus chimera containing Sindbis virus spikes,”J. Virology71(1):818-823 (1997).
Strauss et. al., “The alphaviruses: gene expression, replication, and evolution,”Microbiological Reviews58(3):491-562 (1994).
Van Der Most et. al., “Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.”J. Virology74(17):8094-8101 (2000).
Weiss et al., “Interactions between Sindbis virus RNAs and a 68 amino acid derivative of the viral capsid protein further defines the capsid binding site,”Nucleic Acids Research, vol. 22, No. 5 (pp. 780-786 (1994).
White et. al., “Deletion analysis of a defective interfering Semliki Forest virus RNA genome defines a region in the nsP2 sequence that is required for efficient packaging of the genome into virus particles,”J. Virology, vol. 72, No. 5, pp. 4320-4326 (1998).
Xiong et. al., “Sindbis virus: an efficient, broad host range vector for gene expression in animal cells,”Science 243:1188-1191 (1989).
Yao et. al., “Interactions between PE2, E1, and 6K required for assembly of alphaviruses studied with chimeric viruses.”J. Virology70(11):7910-7920 (1996).
Cheng et al., “Nucleocapsid and glycoprotein organization in an enveloped virus,” Cell. Feb. 24, 1995;80(4):621-30.
Barth et al., “Alphavirus assembly and entry: role of the cytoplasmic tail of the E1 spike subunit,” J Virol. Dec. 1992;66(12):7560-4.
Perri Silvia
Polo John M.
Thudium Kent
Lee Helen
Mosher Mary E
Novartis Vaccines and Diagnostics Inc.
LandOfFree
Chimeric alphavirus replicon particles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric alphavirus replicon particles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric alphavirus replicon particles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4054588